Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316580 | 0.96 | IKBKB (0.47) | IKBKBMAP3K12GBA1GLAALDH1A1 | |
| SCHEMBL10316621 | 0.84 | MAP3K12 (0.48) | IKBKBMAP3K12GLAALDH1A1HPGD | |
| SCHEMBL12099918 | 0.80 | IKBKB (0.52) | IKBKBGBA1GLAALDH1A1HPGD | |
| SCHEMBL1441610 | 0.80 | ALDH1A1 (0.46) | MAP3K12GBA1GLAALDH1A1HPGD | |
| SCHEMBL1441608 | 0.80 | ALDH1A1 (0.46) | MAP3K12GBA1GLAALDH1A1HPGD | |
| SCHEMBL10316582 | 0.79 | CRHBP (0.47) | IKBKBMAP3K12GLAALDH1A1HPGD | |
| SCHEMBL1441492 | 0.76 | IRAK4 (0.43) | MAP3K12GBA1GLAALDH1A1HPGD | |
| SCHEMBL3095284 | 0.75 | IKBKB (0.56) | IKBKBGBA1GLAALDH1A1HPGD | |
| SCHEMBL1442112 | 0.74 | MAPT (0.48) | GBA1ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL1442108 | 0.74 | MAPT (0.48) | GBA1ALDH1A1HPGDGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238547-A1 | 2, 3, 6 - TRIAMINO SUBSTITUTED PYRIDINES AS KV7 (KCNQ) CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-09-20 | — | — | US | claimed |
| EP-2475656-A1 | 2, 3, 6 -TRIAMINO SUBSTITUTED PYRIDINES AS KV7 (KCNQ) CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2012-07-18 | — | — | EP | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20120238547-A1 | 2, 3, 6 - TRIAMINO SUBSTITUTED PYRIDINES AS KV7 (KCNQ) CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-09-20 | — | — | US | disclosed |
| EP-2475656-A1 | 2, 3, 6 -TRIAMINO SUBSTITUTED PYRIDINES AS KV7 (KCNQ) CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238547-A1 | 2, 3, 6 - TRIAMINO SUBSTITUTED PYRIDINES AS KV7 (KCNQ) CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ4 | IKBKB 1140/4885MAP3K12 563/4885GBA1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.